In one deal, Foundation Consumer Healthcare will acquire Teva’s emergency contraception products, including Plan B One-Step and Next Choice One Dose, for $675 million.
Teva will sell its remaining contraception, fertility, menopause and osteoporosis products to CVC Capital Partners Fund VI for $703 million in cash.
Teva will use the money from these deals, along with proceeds from the recent $1.1 billion sale of its intrauterine device, to pay off some loan debt, according to the report.
The deals are expected to close by the end of the year.
More articles on supply chain:
Biosimilars are getting approved, but few have hit the market — here’s why
6 drugmakers in the headlines
FDA approves treatment for common gynecologic infection: 3 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
